华熙生物科技股份有限公司 独立董事提名人声明与承诺 提名人华熙昕宇投资有限公司，现提名陈达亮为华熙生物科技股份有限公司 第三届董事会独立董事候选人，并已充分了解被提名人职业、学历、职称、详细 的工作经历、全部兼职、有无重大失信等不良记录等情况。被提名人已书面同意 出任华熙生物科技股份有限公司第三届董事会独立董事候选人(参见该独立董事 候选人声明)。 提名人认为，被提名人具备独立董事任职资格，与华熙生物科技股份有限公 司之间不存在任何影响其独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 被提名人已经参加培训并已取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： (一)《中华人民共和国公司法》等关于董事任职资格的规定； (二)《中华人民共和国公务员法》关于公务员兼任职务的规定； (三)中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监管 规则以及公司章程有关独立董事任职资格和条件的相关规定； (四)中 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-018 华熙生物科技股份有限公司 关于修订公司章程及新增、修订或废止部分制度细则 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 第二届董事会第十九次会议，审议通过了《关于取消监事会、修订<公司章程> 并办理工商变更登记的议案》《关于修订部分公司管理制度的议案》《关于修订或 废止部分公司管理制度、细则的议案》《关于制定<华熙生物科技股份有限公司内 部审计制度>的议案》，现将具体情况公告如下： 一、 本次修订公司章程及新增、修订或废止部分制度细则的概况 公司根据相关法律法规及规范性文件的要求并结合公司实际情况，新增、修 订或废止部分制度细则，制度细则清单如下，新增、修订后制度细则请见公告附 件。 | 序号 | 名称 | 变更情况 | 是否需要股 | | --- | --- | --- | --- | | | | | 东大会审议 | | 1 | 公司章程 | 修订 | 是 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-019 华熙生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）第二届董事会任期已届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易 所科创板股票上市规则》等法律、法规以及《华熙生物科技股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，公司开展董事会换届选举工作，现 将本次董事会换届提名情况公告如下： 一、 董事会换届提名情况 根据公司章程的规定，公司控股股东华熙昕宇投资有限公司提名赵燕女士、 郭珈均先生、李亦争先生、汪卉先生、于静女士、陈雨鑫先生为公司第三届董事 会非独立董事（候选人简历详见附件）；提名姚洋先生、陈达亮先生、徐文鸣先 生为公司第三届董事会独立董事候选人（候选人简历详见附件），独立董事候选 人姚洋先生、陈达亮先生、徐文鸣先生已参加独立董事培训，并取得上海证券交 易所认可的相关培训证明材料，其中陈达亮先生为会计专业人士。 公司 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-017 华熙生物科技股份有限公司 第二届董事会第十九次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2025 年 5 月 16 日华熙生物科技股份有限公司（以下简称"公司"或"华熙 生物"）以现场结合通讯方式召开了第二届董事会第十九次会议，会议通知及会 议材料已于 2025 年 5 月 11 日以电子邮件形式发出。本次会议由董事长赵燕女士 主持，本次会议应出席董事 9 人，实际出席并表决董事 9 人，公司监事及部分高 级管理人员列席了本次董事会。会议的召集、召开程序符合《中华人民共和国公 司法》等相关法律法规与《公司章程》等内部制度的规定。 二、董事会会议审议情况 (一) 审议通过《关于取消监事会、修订〈公司章程〉并办理工商变更登 记的议案》 表决结果：9 票赞成，0 票弃权，0 票反对。 具 体 内 容 详 见 公 司 于 2025 年 5 月 20 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com. ...

Core Viewpoint - The article published by Huaxi Biological refutes the notion that hyaluronic acid is "outdated," arguing that this perspective is a product of "impatient capital" attempting to divert attention from the necessary evolution of China's industry [1][2]. Group 1: Industry Analysis - The rise of the "hyaluronic acid is outdated" theory is characterized as a mirage created by certain capital forces, aiming to shift focus towards new investment themes and companies [2]. - Huaxi Biological directly names several brokerage research reports, including those from Western Securities, which have contributed to the spread of misleading comparisons against the hyaluronic acid industry [2][3]. - The misleading conclusions associated with the "hyaluronic acid is outdated" narrative have been widely disseminated by media and influencers, damaging the market foundation of a competitive Chinese industry [3]. Group 2: Company Performance - Huaxi Biological's stock, once reaching a peak of 309.43 yuan per share, has been on a downward trend since July 2021, closing at 50.6 yuan per share on May 19, with a slight increase of 0.22% [3]. - The company staff indicated that stock price fluctuations are influenced by a combination of factors, and they have not yet experienced any legal disputes related to the article [3].

作 者丨见习记者李益文 编 辑丨刘巷 江佩佩 2 0 0亿市值医美巨头，突然向券商"开炮"！ 5月1 7日深夜2 3点4 1分，华熙生物在其官方微信号发布 《概念总在重演，科技永远向前》 的文章，对当下 "玻尿酸过时" 的市场观点发起驳 斥。 华熙生物发文称，"这个经历了几代中国科学家努力的产业在近几年资本市场的概念切换中遭遇了谎言与践踏 "。 文章称， 透明质酸"过时论"的兴起，本质上是一场由"浮躁资本"构建的题材幻象 ，试图用"神话过时"绕开中国产业发展必然面临的进阶过 程，引导资本和市场资源聚焦于资本新题材，用"新贵登场"塑造沙土高楼。 多家券商研报被点名 值得注意的是， 华熙生物在文章中直接点名 ，包含西部证券在内的多家券商研究所的研究报告 。并表示，为了营造比透明质酸产业更大的预 期，围绕某重组胶原企业的研报中，出现了大量直接针对中国透明质酸产业的所谓"对比研究"。所有人都可以检索到这些大量散布的"研究报 告"来自哪家机构、围绕哪家企业、发布于什么时间，他们的名字与误导性言论被永久地记录在了互联网的世界里。 华 熙 生物 表示， 这 些 误 导 性 " 结 论 " 伴 随 着 随 后 兴 起 的 " ...

Group 1 - The article emphasizes that the collagen protein concept has gained attention in the capital market since 2022, overshadowing the hyaluronic acid industry, which has been misrepresented in various research reports [1] - It highlights that misleading conclusions comparing collagen protein to hyaluronic acid have been widely circulated, damaging the market foundation of a competitive Chinese industry [1] - The rise of the "outdated hyaluronic acid" narrative is described as a phenomenon driven by "impatient capital," which attempts to divert focus from the necessary evolution of the industry [1] Group 2 - The article points out that while hyaluronic acid is being simplistically labeled as just a "moisturizer," there is a significant increase in research surrounding it, with approximately 47,000 published papers from 2000 to 2024 [2] - Over 60% of the research on hyaluronic acid focuses on advanced fields in life sciences, including immunity, metabolism, cell differentiation, cancer research, and signaling mechanisms [2]

Market Overview - The Shanghai Composite Index fell by 0.40% on May 16, with 15 industries experiencing gains, led by the automotive and machinery sectors, which rose by 1.91% and 0.83% respectively [1] - The beauty and personal care sector had the largest decline, dropping by 1.31%, followed by the non-bank financial sector, which fell by 1.21% [1] Capital Flow Analysis - The net inflow of capital in the two markets was 307 million yuan, with 14 industries seeing net inflows. The automotive sector led with a net inflow of 4.616 billion yuan, while the basic chemical industry had a net inflow of 1.981 billion yuan and a daily increase of 0.60% [1] - Conversely, 17 industries experienced net outflows, with the non-bank financial sector seeing the largest outflow of 1.925 billion yuan, followed by the transportation sector with a net outflow of 1.250 billion yuan [1] Beauty and Personal Care Sector - The beauty and personal care sector saw a decline of 1.31% with a net outflow of 294 million yuan. Out of 31 stocks in this sector, 11 rose while 20 fell [2] - The stocks with the highest net inflow included Qingdao Kingking with 50.67 million yuan, followed by Zhongshun Jierou and Yiyi Co., with net inflows of 20.55 million yuan and 9.64 million yuan respectively [2] - Notable stocks with significant net outflows included Furuida with 151 million yuan, Aimeike with 49.19 million yuan, and Qingsong Co. with 38.32 million yuan [2] Individual Stock Performance - The top stocks in the beauty and personal care sector based on capital flow include: - Furuida: -3.82% with a net outflow of 150.98 million yuan [3] - Aimeike: -2.06% with a net outflow of 49.19 million yuan [3] - Qingsong Co.: -7.34% with a net outflow of 38.32 million yuan [3] - Other notable performers include: - Qingdao Kingking: +1.89% with a net inflow of 50.67 million yuan [3] - Zhongshun Jierou: +0.87% with a net inflow of 20.55 million yuan [3]

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经公司研究院 作者：新消费主张/cici 截至2025年4月30日，日化护肤上市公司已完成2024年财报的披露，对此我们挑选了14家具有代表性的 上市公司进行库存状况分析。 在我们所选取的日化护肤公司中，2024年，从存货规模及存货占总资产比例变化来看水羊股份存货占全 部资产的比重较高，约为19.52%；从存货周转效率来看，仅有丸美股份、青松股份2家公司存货周转状 况有所改善，其余8家公司存货周转天数均不同程度变长，相应的存货周转效率不同程度下降。 其中最值得一提的便是锦波生物、华熙生物、贝泰妮这三家上市公司，首先，这三家上市公司的存货规 模及存货占总资产的比例均有所提升；其次，这三家上市公司的存货周转天数均超出了270天（9个月） 且存货周转效率仍进一步下降。 存货规模&占比：过半数公司存货规模及占比双增 水羊股份存货占比最高 | | | 存货规模(亿)及同比变动 | | | --- | --- | --- | --- | | | 2023年 | 2024年 | 同比 | | 创尔生物 | 7.97 | 6.61 | 62 ...